• Return to HOME


  • Home
  • Services
    • Clinical & Medical Consulting
    • Business Development
    • Pharmaceutical
    • Regulatory Affairs
    • Legal Consulting
  • Our Team
    • Michael Epstein, MD, FACG, AGAF
  • News
  • Blog
  • Contact


Biosimilars: The Need, The Challenge, The Future: The FDA Perspective

May 20, 2015
by Epstein Associates
Comments are off

Biosimilars  The Need, The Challenge, The Future  The FDA Perspective_ Epstein, et al_Page_1This article summarizes the brief history of the biosimilars industry, the FDA’s regulations and guidance for biosimilars development, and the issues and challenges facing developers and regulators in bringing biosimilars to market.

Download the PDF White Paper: Biosimilars The Need, The Challenge, The Future The FDA Perspective Epstein, et al

Social Share
  • google-share

Key Services

  • Clinical & Medical Consulting
  • Business Development
  • Pharmaceutical
  • Regulatory Affairs
  • Legal Consulting

News & Announcements

Achieving successful bowel preparation with evening/morning split-dosing regimens of NER1006 versus trisulfate: post hoc analysis of a Phase 3 trial
Jul 25, 2017
Novel 1L Polyethylene Glycol (PEG)-Based Bowel Preparation NER1006 Achieves High Quality Bowel Cleansing with a Lower Volume than Standard 2L PEG + Ascorbate and Under 3L Total Fluid Volume Intake
Jul 25, 2017
Bowel preparation quality of NER1006 versus oral trisulfate solution as assessed by colonoscopists at site: a post hoc analysis from a randomized controlled trial
Jul 25, 2017

410-224-4887 x453

Epstein Associates, LLC
621 Ridgely Avenue, Suite 204
Annapolis, MD 21401

  • Home
  • Services
  • Our Team
  • News
  • Blog
  • Contact

© Copyright 2015, Epstein Associates, LLC
Website Design by Calvert Design Group, Inc.